Blog
Drug Target Encyclopedia Series (36) —CD152
Release Time：
2026-04-16 09:38
CD152 (CTLA-4) is a well-established immune checkpoint receptor primarily expressed on activated T cells and regulatory T cells (Tregs). By competing with CD28 for binding to CD80/CD86, CTLA-4 acts as a negative regulator of T-cell activation and plays a central role in maintaining immune homeostasis.
CTLA-4 has become one of the most important targets in cancer immunotherapy, especially in the development of checkpoint inhibitors and next-generation immune modulators. It is also highly relevant in autoimmune disease research, Treg biology, and combination immuno-oncology strategies.
CTLA-4 is highly relevant in:
• Melanoma
• Non-small cell lung cancer (NSCLC)
• Renal cell carcinoma (RCC)
• Hepatocellular carcinoma (HCC)
• Immune regulation and autoimmune disorders
Targeting CTLA-4 in immunotherapy:
🧪 Monoclonal antibodies (mAbs) – CTLA-4 antibodies were among the first to validate immune checkpoint blockade as a transformative therapeutic strategy in oncology.
🧪 Combination therapies – CTLA-4 is widely explored in combination with PD-1/PD-L1 inhibitors to enhance anti-tumor immune responses.
🧪 Fc-engineered antibodies – New designs aim to improve efficacy through better Treg depletion and immune activation in the tumor microenvironment.
🧪 Bispecific antibodies – Emerging CTLA-4-based bispecific formats are being developed for more selective and differentiated immunotherapy approaches.
🧪 Tumor-selective strategies – Next-generation programs are focused on reducing systemic toxicity while preserving anti-tumor benefit.
💥 Challenges include:
• Immune-related adverse events associated with systemic checkpoint blockade
• Limited therapeutic window in some patient populations
• Balancing efficacy with safety in combination regimens
🔬 Ongoing research is advancing safer CTLA-4-targeted molecules, optimized combination regimens, and novel multispecific formats designed to improve response durability and tolerability across solid tumors.
Need CD152 tools for your research?
Fill out the form below, or visit the link: to browse the complete list of available in-stock products.
E-mail：support@levostar.com
USA
16192 Coastal Hwy，Lewes, DE 19958
TEL：619-537-9202
China
A3-502 No.328, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123
TEL：0512-62888898